NASDAQ:MLND

Millendo Therapeutics Stock Forecast, Price & News

$0.99
-0.04 (-3.88 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$0.97
Now: $0.99
$1.06
50-Day Range
$1.04
MA: $1.79
$2.33
52-Week Range
$1.03
Now: $0.99
$3.64
Volume799,574 shs
Average Volume918,460 shs
Market Capitalization$18.85 million
P/E RatioN/A
Dividend YieldN/A
Beta1.12
Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.
Millendo Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MLND
CUSIPN/A
CIKN/A
Phone734-845-9000
Employees12
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.28 per share

Profitability

Net Income$-44,570,000.00

Miscellaneous

Market Cap$18.85 million
Next Earnings Date5/14/2021 (Estimated)
OptionableNot Optionable

Headlines

Tempest and Millendo Announce Proposed Merger Agreement
March 29, 2021 |  finance.yahoo.com
Millendo Therapeutics, Inc. (3OS1.F)
December 19, 2020 |  in.finance.yahoo.com
Is MLND A Good Stock To Buy Now?
December 10, 2020 |  finance.yahoo.com
Millendo Therapeutics EPS beats by $0.12
November 9, 2020 |  seekingalpha.com
See More Headlines

MarketRank

Overall MarketRank

1.53 out of 5 stars

Medical Sector

479th out of 2,024 stocks

Pharmaceutical Preparations Industry

232nd out of 772 stocks

Analyst Opinion: 3.2Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -
$0.99
-0.04 (-3.88 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MLND News and Ratings via Email

Sign-up to receive the latest news and ratings for MLND and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Millendo Therapeutics (NASDAQ:MLND) Frequently Asked Questions

Is Millendo Therapeutics a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Millendo Therapeutics in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Millendo Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MLND, but not buy additional shares or sell existing shares.
View analyst ratings for Millendo Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Millendo Therapeutics?

Wall Street analysts have given Millendo Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Millendo Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Millendo Therapeutics?

Millendo Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 506,400 shares, an increase of 62.5% from the March 15th total of 311,600 shares. Based on an average trading volume of 870,700 shares, the days-to-cover ratio is currently 0.6 days.
View Millendo Therapeutics' Short Interest
.

When is Millendo Therapeutics' next earnings date?

Millendo Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, May 14th 2021.
View our earnings forecast for Millendo Therapeutics
.

How were Millendo Therapeutics' earnings last quarter?

Millendo Therapeutics, Inc. (NASDAQ:MLND) issued its quarterly earnings data on Sunday, March, 28th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $0.05.
View Millendo Therapeutics' earnings history
.

How has Millendo Therapeutics' stock been impacted by COVID-19?

Millendo Therapeutics' stock was trading at $6.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MLND stock has decreased by 85.0% and is now trading at $0.99.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MLND?

6 brokers have issued 12-month price targets for Millendo Therapeutics' stock. Their forecasts range from $2.00 to $6.00. On average, they expect Millendo Therapeutics' share price to reach $3.80 in the next twelve months. This suggests a possible upside of 283.8% from the stock's current price.
View analysts' price targets for Millendo Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Millendo Therapeutics' key executives?

Millendo Therapeutics' management team includes the following people:
  • Dr. Julia C. Owens Ph.D., Exec. Chair of Board (Age 47, Pay $702.8k)
  • Mr. Louis J. Arcudi III, M.B.A., MBA, CEO, Pres & Director (Age 60, Pay $495.79k)
  • Ms. Jennifer Lynn Minai-Azary, CFO & Principal Accounting Officer
  • Mr. Jeffery M. Brinza J.D., Interim Gen. Counsel (Age 59)
  • Ms. Denise Dorigo Jones, VP of HR
  • Mr. Thomas Hoover, Chief Bus. Officer

Who are some of Millendo Therapeutics' key competitors?

What other stocks do shareholders of Millendo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Millendo Therapeutics investors own include Allena Pharmaceuticals (ALNA), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Acasti Pharma (ACST), Onconova Therapeutics (ONTX), TherapeuticsMD (TXMD), Bionano Genomics (BNGO), DURECT (DRRX), Geron (GERN) and Heat Biologics (HTBX).

What is Millendo Therapeutics' stock symbol?

Millendo Therapeutics trades on the NASDAQ under the ticker symbol "MLND."

How do I buy shares of Millendo Therapeutics?

Shares of MLND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Millendo Therapeutics' stock price today?

One share of MLND stock can currently be purchased for approximately $0.99.

How much money does Millendo Therapeutics make?

Millendo Therapeutics has a market capitalization of $18.85 million. The company earns $-44,570,000.00 in net income (profit) each year or ($3.25) on an earnings per share basis.

How many employees does Millendo Therapeutics have?

Millendo Therapeutics employs 12 workers across the globe.

What is Millendo Therapeutics' official website?

The official website for Millendo Therapeutics is www.millendo.com.

Where are Millendo Therapeutics' headquarters?

Millendo Therapeutics is headquartered at 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104.

How can I contact Millendo Therapeutics?

Millendo Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The company can be reached via phone at 734-845-9000 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.